Jeffrey Hager, Ph.D., Co-Founder and SVP, Head of Biology, IDEAYA Biosciences
IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and San Diego, California.
A major focus of IDEAYA is to exploit the concept of synthetic lethality, a phenomenon whereby the independent loss-of-function of two different genes have no significant effects on cell growth and viability, but when combined results in robust cell death. Synthetic lethality while a longstanding concept in genetic model systems and cancer biology has only recently been translated into a therapeutic reality with the approval of a PARP-inhibitor, olaparib, in BRCA deficient ovarian cancer. IDEAYA will focus on novel synthetic lethal interactions for genetically defined patient populations, exploiting inherent tumor susceptibilities en-route to discovery and development of small-molecule agents to treat major human cancers. Another area of focus for IDEAYA will be to exploit the potential of modulating DNA repair to augment response to immunotherapy. In addition, drug discovery programs will target pathways known to produce an immune suppressed tumor microenvironment, enabling tumors to escape recognition by the host immune system.